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Aims Despite the increased prevalence of atrial fibrillation (AF), data for the implementation of nationwide screening pro-
grammes are limited. The aim of this national screening study was to increase nationwide awareness about AF and
stroke risk, to determine the prevalence of AF in Belgian general population using an ECG handheld machine and its
feasibility to identify new AF cases.
Methods and
results
We analysed data obtained from 5 years of the ‘Belgian Heart RhythmWeek’ screening programme. All subjects were
screened using a one-lead ECG handheld machine. Among 65 747 subjects screened, AF was recorded in 911, with an
overall prevalence of 1.4% [95% confidence interval (CI) 1.2–1.6%]. High thrombo-embolic risk, as assessed by CHA2-
DS2-VASc score ≥2, was recorded in 69% of AF subjects. In subjects with high thrombo-embolic risk, only 5.4% were
treated with oral anticoagulant (OAC) and 5.8% were treated with OAC and antiplatelet drugs. Among recorded AF
cases, the use of the ECG handheld machine allowed identification of 603 new AF patients (1.1%, 95% CI 0.9–1.3%).
Factors associated with incident AF were chronic heart failure (P, 0.001), age (P, 0.001), diabetes mellitus
(P, 0.001), previous stroke (P, 0.001), vascular disease (P, 0.001), and male sex (P, 0.001).
Conclusion In this Belgian national screening programme, prevalence of AF was 1.4%. The use of an ECG handheld machine is feas-
ible to identify a significant number of new AF cases, most with a high thrombo-embolic risk. Given the low OAC use
recorded, greater efforts in AF detection and treatment are urgently needed to reduce the burden of stroke associated
with this common arrhythmia.
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Introduction
The prevalence of atrial fibrillation (AF) is progressively increasing
and in the USA, has been estimated to reach up to 12 million pa-
tients in 2050.1 Despite this, up to 40% of AF patients remain asymp-
tomatic and undiagnosed, exposing such patients to the risks of AF
such as stroke and heart failure.2,3 A recent systematic review
exploring the issue of post-stroke AF diagnosis found that up to
16.9% of patients with a cryptogenic stroke are diagnosed with AF
in one of the post-stroke phases, both early and late ones, with an
overall 23.7% of patients diagnosed after the occurrence of stroke.4
The development of screening strategies for early detection of AF
could be a solution, especially since opportunistic screening for AF
in all patients aged ≥65 is recommended in guidelines.5 One
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consideration is to choose between a systematic or opportunistic
approach to screening.6 In a large systematic review, a similar high
percentage of AF cases could be diagnosed in both screening
approaches, in particular among patients aged 65 and more.6 One
large randomized controlled trial demonstrated that opportunistic
screening could be more cost-effective than a systematic approach
to screening.7
One possible advance in the development of effective systematic
screening programmes could be the use of innovative new tech-
nologies to detect AF.6,8 One recent study explored the possibility
to detect AF using an iPhone one-lead ECG probe.9 This study
(SEARCH-AF) demonstrated that using this highly technological
system, coupled with an automated interpretation system, could
obtain high levels of both sensitivity and specificity in detecting
AF, with an improvement in cost-effectiveness and treatment
adherence.9
The aim of this national screening study was to determine the
prevalence of AF in Belgium using a one-lead ECG handheld ma-
chine (Omronw HeartScan HCG-801, Colin, Australia) on a popu-
lation screened during 5 years of the ‘Belgian Heart Rhythm Week’
screening programme.10 Secondly, we evaluated AF-related
thrombo-embolic risk in our screened population. Lastly, we as-
sessed clinical factors associated with incident AF diagnosis.
Methods
Study design
As previously reported, the ‘Belgian Heart Rhythm Week’ is a Belgian
national campaign on awareness about cardiac arrhythmias, designed
along with an untargeted voluntary screening programme organized
by the Belgian Hearth Rhythm Association (BeHRA) held 1 week a
year from 2010 to 2014.10 All adult (age ≥18 years) subjects were in-
vited, on a voluntarily basis, to participate in a free screening programme
in 89 national hospitals in Belgium. During every year edition of the
‘Belgian Heart RhythmWeek’ in all the country, the screening campaign
was advertised through press conferences, a massivemedia campaign on
the national radio, newspapers, and magazines, and via the distribution
of flyers and posters in all national hospitals and general practitioner
services.
The study protocol was approved by the Ethics Committee of all
participating medical centres and each patient signed an informed
consent form before participating. The National Government was
consulted regarding the privacy law on the data collection. The study
was conducted in accordance with the EU Note for Guidance on
Good Clinical Practice CPMP/ECH/135/95 and the Declaration of
Helsinki.
None of the subjects that took part in the programme was ever
previously identified or selected as eligible for taking part. All the
subjects reached one of the hospital in which the programme took
part by themselves or were randomly picked among those people inci-
dentally present in the hospitals. It was clearly stated that taking part in
the programme would have not implied a free consultation with a
cardiologist.
All subjects filled out a questionnaire to collect demographic vari-
ables (sex and age), any prior diagnosis of AF, the presence of the vari-
ous risk factors evaluated computing the CHA2DS2-VASc
11
thrombo-embolic risk evaluation score. From 2012 to 2014, data on an-
tithrombotic therapies were also collected. Every subject then under-
went a 30 s one-lead ECG recording with an ECG handheld machine
(Omronw, HeartScan HCG-801), that was previously validated and
compared with a standard ECG as highly accurate to detect ECG
changes and established arrhythmias, in particular the presence of
AF.12 All the procedures were nurse-led.
The presence of AF was defined as follows: (i) the surface ECG shows
‘absolutely’ irregular RR intervals, (ii) there are no distinct P waves on
the surface ECG, and (iii) the atrial cycle length (when visible), i.e. the
interval between two atrial activations, is usually variable and
,200 ms (.300 bpm). Whenever the device detected the presence
of AF, according to the criteria defined above, the ECG strip was
checked by the on-site cardiologist for confirmation. Whether the
ECG was unclear a 12-lead standard ECG was taken as soon as possible
to confirm the presence of AF. Participants with diagnosed AF during
the screening (AF group) were referred to consult their general practi-
tioner or cardiologist.
Thrombo-embolic risk was categorized according to the CHA2DS2-
VASc score.11 ‘Low-risk’ patients were defined as males and
females with no other risk factors for stroke (i.e. a CHA2DS2-VASc ¼ 0
in males, or 1 in females); ‘moderate risk’ was defined as male
patients with CHA2DS2-VASc ¼ 1; ‘high risk’ as CHA2DS2-VASc
score ≥2.11
Statistical analysis
All continuous variables were tested for normality with the Shapiro–
Wilk test. Variables with normal distribution were expressed as means
and standard deviations (SD), and tested for differences with the
Student’s t-test. Non-normal variables were expressed as median and
interquartile range (IQR) and differences tested with the Mann–Whit-
ney U test. Categorical variables, expressed as counts and percentages,
were analysed by a x2 test.
A regression analysis was performed, after excluding all the subjects
with previous AF, to establish clinical factors significantly associated with
an incident AF diagnosis. All variables that were significantly different be-
tween the two groups at the baseline underwent a univariate analysis
and those univariate predictors with a statistical significance of ,10%
were inserted into a forward multivariate logistic model. A two-sided
P-value ,0.05 was considered as statistically significant. All analyses
were performed using SPSS v. 22.0 (IBM, NY, USA).
Results
Among the 82 569 subjects enrolled in the screening programme
from 2010 to 2014, all subjects aged ≥20 with complete data about
demographic characteristics and clinical risk factors were selected,
obtaining a total of 65 747 selected subjects available for the present
analysis (Figure 1). Median age was 58 years [48–66 IQR], and 58.6%
(n ¼ 38 548) were female.
What’s new?
† Systematic community screening programmes based on sim-
ple use of an ECG handheld machine is feasible to identify a
significant number of new AF cases, most with a high risk of
stroke and thrombo-embolism.
† Given the low use of OAC among recorded AF patients,
greater screening efforts for AF detection are urgently
needed to reduce the burden of stroke associated with this
common arrhythmia.
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Atrial fibrillation prevalence and clinical
characteristics
Of the selected cohort, AF was recorded in 911 subjects with a
prevalence of 1.4% [95% confidence interval (CI) 1.2–1.6%], being
higher in males (1.8%) than in females (1.1%). In subjects with age
≥65, AF prevalence was 2.3%, compared with 1.0% in those aged
,65. The prevalence of AF was 6.5% in the 85–89 years age strata.
Male subjects had a significantly higher AF prevalence than females
between 30 and 34 years (P, 0.05) and in the age strata 65–69,
70–74, 75–79, and 80–84 years (P, 0.05). Prevalence of AF diag-
nosis according to age and gender is shown in Figure 2.
Demographic and clinical characteristics of the AF and sinus
rhythm screened populations are summarized in Table 1. Subjects
with AF were older andmore likely to bemales, comparedwith sub-
jects with sinus rhythm (P, 0.001). Subjects with AF had a higher
prevalence of congestive heart failure (CHF), diabetes, stroke, and
vascular disease than subjects with sinus rhythm (all P, 0.001).
Thrombo-embolic risk as measured by the CHA2DS2-VASc score
was higher in subjects with AF compared with subjects with sinus
rhythm (P, 0.001).
CHA2DS2-VASc score and distribution
of risk factors
Among the 911 subjects with AF, low-risk patients (i.e. CHA2DS2-
VASc score 0 in males or CHA2DS2-VASc score 1 in females) was
found in 78 (8.6%) males and in 103 (11.3%) females, respectively.
Total enrolled
patients
n = 82 569
Excluded patients
for incomplete
clinical data
n = 16 822
Total available
patients for analysis
n = 65 747
Atrial fibrillation
n = 911
Sinus rhythm
n = 64 836
2010
n = 13 564
2011
n = 20 209
2012
n = 21 586
2013
n = 16 905
2014
n = 10 305
Figure 1 Study flow chart for subjects’ selection.
Figure 2 Prevalence of AF in the overall population according to gender and age. M, males; F, females.
Population-wide systematic screening for new-onset AF 1781
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CHA2DS2-VASc score equal to 1 was found in 101 males (11.1%).
High thrombo-embolic risk, defined as CHA2DS2-VASc ≥2, was
recorded in 69.0% (n ¼ 629) of the subjects.
In male subjects with CHA2DS2-VASc 1, age 65–74 category was
the most common risk factor (67.3%). Hypertension was recorded
in 18.8%, while CHF in 9.9%. Only 2% of these patients reported
vascular disease. In subjects at high thrombo-embolic risk (CHA2-
DS2-VASc ≥2), the most prevalent risk factors were hypertension
(53.1%) and vascular disease (44.2%).
Clinical predictors of incident AF
From the questionnaire answers, a total of 13 006 subjects, i.e.
19.8% of the overall analysed population, were found to have re-
ported a previous diagnosis of AF. In order to analyse clinical factors
associated with the occurrence of a ‘new-onset’ incident AF, these
patients were excluded, leaving 52 741 subjects available for this
analysis. Of these, 603 subjects (1.1%, 95% CI 0.9–1.1%) had inci-
dent AF, from the total of 911 AF subjects. Compared with the
308 patients with previous AF (Table 2), patients with incident AF
had less prevalent hypertension, diabetes, CHF, stroke, and vascular
disease (all P, 0.001). Patients with previous AF were more
commonly aged 65–74 and ≥75 (P ¼ 0.002), and thus, higher
thrombo-embolic risk (P, 0.001).
On multivariable logistic regression analysis for incident
AF, the final forward model demonstrated that CHF (P, 0.001),
age 65–74 (P, 0.001) and age ≥75 (P, 0.001), diabetes (P,
0.001), previous stroke (P, 0.001), previous diagnosis of vascular
disease (P, 0.001), and sex (i.e. male) category (P, 0.001) were
significantly associated with incident AF (Table 3).
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Demographic and clinical characteristics
distribution
Sinus
rhythm
(n5 64 836)
Atrial
fibrillation
(n 5 911)
P-value
Age, years (median [IQR]) 58 [48–66] 65 [51–74] ,0.001a
Age class ,0.001b
,65 years, n (%) 45 275 (69.8) 451 (49.5) ,0.05c
65–74 years, n (%) 14 100 (21.7) 247 (27.1) ,0.05c
≥75 years, n (%) 5461 (8.4) 213 (23.4) ,0.05c
Heart rated, bpm
(median [IQR])
78 [69–88] 78 [68–92] 0.593a
Sex category ,0.001b
Male, n (%) 26 703 (41.2) 496 (54.4)
Female, n (%) 38 133 (58.8) 415 (45.6)
Congestive heart failure, n (%) 13 019 (20.1) 289 (31.7) ,0.001b
Hypertension, n (%) 23 477 (36.2) 353 (38.7) 0.113b
Diabetes, n (%) 13 802 (21.3) 244 (26.8) ,0.001b
Stroke, n (%) 12 712 (19.6) 244 (26.8) ,0.001b
Vascular disease, n (%) 14 906 (23.0) 280 (30.7) ,0.001b
Previous AF diagnosis, n (%) 12 698 (19.6) 308 (33.8) ,0.001b
CHA2DS2-VASc, median [IQR] 2 [1–3] 3 [1–5] ,0.001
a
AF, atrial fibrillation; IQR, interquartile range.
aMann–Whitney U test.
bx2 test.
cBonferroni correction.
dData about 53 406 subjects.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Demographic and clinical characteristics
distribution of AF subjects according to the presence of
previous AF
Previous AF
(n5 308)
Incident AF
(n5 603)
P-value
Age, years (median [IQR]) 65 [45–76] 65 [52–73] 0.982
Age class 0.002
,65 years, n (%) 152 (49.4) 299 (49.6) NSa
65–74 years, n (%) 66 (21.4) 181 (30.0) ,0.05a
≥75 years, n (%) 90 (29.2) 123 (20.4) ,0.05a
Heart rateb, bpm
(median [IQR])
77 [68–91] 78 [68–92] 0.200
Sex category 0.922
Male, n (%) 167 (54.2) 329 (54.6)
Female, n (%) 141 (45.8) 274 (45.4)
Congestive heart failure, n (%) 219 (71.1) 70 (11.6) ,0.001
Hypertension, n (%) 162 (52.6) 191 (31.7) ,0.001
Diabetes, n (%) 154 (50.0) 90 (14.9) ,0.001
Stroke, n (%) 169 (54.9) 75 (12.4) ,0.001
Vascular disease, n (%) 176 (57.1) 104 (17.2) ,0.001
CHA2DS2-VASc, median
[IQR]
5 [3–6] 2 [1–3] ,0.001
CHA2DS2-VASc risk classes ,0.001
Low, n (%) 9 (2.9) 172 (28.5) ,0.05a
Intermediate, n (%) 17 (5.5) 84 (13.9) ,0.05a
High, n (%) 282 (91.6) 347 (57.5) ,0.05a
AF, atrial fibrillation; IQR, interquartile range; NS, non-significant.
aBonferroni correction.
bData about 51 489 subjects.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Table 3 Multivariable logistic analysis for incident AF
diagnosis
Multivariable model
b OR CI P-value
Congestive heart failure 0.509 1.66 1.25–2.22 0.001
Age class ,0.001
,65 years (ref) – – – –
65–74 years 0.559 1.75 1.45–2.11 ,0.001
≥75 years 1.710 3.22 2.60–4.00 ,0.001
Diabetes 0.440 1.55 1.22–1.99 ,0.001
Stroke 0.736 2.09 1.58–2.76 ,0.001
Vascular disease 0.297 1.35 1.06–1.71 0.015
Sex category (male) 0.418 1.54 1.30–1.81 ,0.001
CI, confidence interval; ref, reference group; OR, odds ratio.
M. Proietti et al.1782
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Antithrombotic therapy
Concomitant antithrombotic therapy was recorded only for sub-
jects enrolled from 2012 to 2014. This enrolled population com-
prised 38 434 subjects, and of these, 417 (1.1%, 95% CI 0.9–1.3%)
of the total of 911 AF subjects, were found to be in AF.
Clinical characteristics for this AF cohort were similar to that
reported in the overall study population, except for hypertension
that was significantly more prevalent in AF subjects compared
with those in sinus rhythm (38.4 vs. 28.7%, P, 0.001). Diabetes
mellitus prevalence was lower in this cohort (7.0%) compared
with the overall study population; however, AF subjects were
more commonly diabetic compared with subjects with sinus rhythm
(9.8 vs. 6.8%, P ¼ 0.017). The proportion at high thrombo-embolic
risk was similar to that reported for the overall AF cohort, that is,
268 (64.3%) of AF subjects.
Data on antithrombotic therapies (available for 406 out of 417 AF
subjects) (Figure 3) are reported in Table 4. Among the AF subjects
with high thrombo-embolic risk, only 5.4% (14 subjects) were
treated with oral anticoagulant (OAC) monotherapy and 5.8%
(15 subjects) were treated with both OAC and antiplatelet drugs.
In the group of subjects with newly diagnosed AF (n ¼ 318 subjects)
only 4 (1.3%) were treated with OAC alone and 2 (0.6%) were trea-
ted with antiplatelet drugs and OAC. Of the subjects with previous
reported AF diagnosis (n ¼ 94 subjects, 23.2%), OAC monotherapy
was used in only 14 (14.9%), and antiplatelet plus OAC was used
in 13 (13.8%) subjects.
Discussion
In this study, we describe for the first time Belgian AF prevalence
among unselected adult population, based on a national screening
study performed 1 week a year from 2010 to 2014, as part of the
‘Belgian Heart RhythmWeek’10 Second, we show how a systematic
screening with a handheld ECG is capable to diagnose a large num-
ber of incident AF cases. Last, we report clinical factors associated
2012 – 2014
AF patients
n = 417
AF patients available
for analysis
n = 406
Previous reported
AF diagnosis
n = 94
Newly diagnosed
AF
n = 312
No data on
antithrombotic therapy
n = 11
Figure 3 Flow-chart for patients with available data about
antithrombotic therapy.
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Table 4 Antithrombotic therapy distribution according to thrombo-embolic risk category in AF subjects from the 2012–
2014 cohort
All subjects (n 5 406) Low risk (n5 89) Intermediate risk (n5 57) High risk (n 5 260) P-value*
Antithrombotic therapy, n (%) 0.006
None therapy 88 (98.9) 51 (89.5) 216 (83.1)
Antiplatelets only 0 (0) 3 (5.3) 15 (5.8)
Oral anticoagulant only 1 (1.1) 3 (5.3) 14 (5.4)
Antiplatelets and oral anticoagulant 0 (0) 0 (0) 15 (5.8)
Previous AF (n5 94) Low risk (n5 5) Intermediate risk (n5 9) High risk (n 5 80) P-value*
Antithrombotic therapy, n (%) 0.301
None therapy 5 (100) 6 (66.7) 50 (62.5)
Antiplatelets only 0 (0) 0 (0) 6 (7.5)
Oral anticoagulant only 0 (0) 3 (33.3) 11 (13.8)
Antiplatelets and oral anticoagulant 0 (0) 0 (0) 13 (16.2)
Incident AF (n5 312) Low risk (n5 84) Intermediate risk (n5 48) High risk (n 5 180) P-value*
Antithrombotic therapy, n (%) 0.309
None therapy 83 (98.8) 45 (93.8) 166 (92.2)
Antiplatelets only 0 (0) 3 (6.2) 9 (5.0)
Oral anticoagulant only 1 (1.2) 0 (0) 3 (1.7)
Antiplatelets and oral anticoagulant 0 (0) 0 (0) 2 (1.1)
AF, atrial fibrillation.
*P-value is about differences in distribution of antithrombotic therapy across the different thrombo-embolic risk categories.
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with the occurrence of incident AF and the suboptimal use of OAC
in this simple nationwide community based programme that is exe-
cuted 1 week per year.
Overall, AF prevalence recorded in Belgium was similar to previ-
ously reported prevalence rates.13 In keeping with prior studies, we
show a higher prevalence rate in male than in female subjects and
among older subjects.14–16 Of note, our study documented a high
peak of prevalence in 30–34 years age strata differently from which
previously reported, even if the unexpected higher prevalence of AF
could be due to the small number of subjects in those age strata.
Conversely, also the presence of other concomitant reversible trig-
ger factors (e.g. alcohol abuse, obesity, intense physical activity)
could possibly explain this unusual incidence peak. Compared
with the EORP-AF Pilot Study,17 we found a higher proportion of
‘low-risk’ subjects, while subjects with high thrombo-embolic risk
was less represented in our cohort than in the EORP-AF pa-
tient.17,18 Nevertheless, this difference in proportion of ‘high-risk’
subjects could reflect the different setting of the studies. Indeed,
our data come from a large community-based screening, while
EORP-AF was based on cardiologist-centred services. In this con-
text, our data are an important representation of thrombo-embolic
risk in the ‘real-life’ general AF population.
As emphasized in guidelines, trying to identify AF before the occur-
rence of major complications is an important objective.5 The ESC
guidelines recommend that every subject aged 65 or older be part
of opportunistic screening by pulse palpation and confirming AF using
a 12-leads ECG,5 as based on how the SAFE study was performed.19
The latter showed that opportunistic screening in subjects at 65 years
old or above was able to identify up to around 1.6% with a new AF
diagnosis. More recently, the SEARCH-AF study identified new AF
cases using an iPhone one-lead ECG probe identifying AF in 1.5%
of the study cohort in community-based pharmacies.9 Moreover,
the economic analysis showed that using technological devices to
identify AF through a systematic community-screening programme
was feasible and cost-effective.
Furthermore, our results reinforce the concept that even in elderly
patients systematic screening procedures are able to detect a signifi-
cant number of patients with untreated AF. Indeed, very recent data
coming from the STROKESTOP study showed that in an unselected
population of patients aged 75–76, a previously undetected AF diag-
nosis was posed in 3.0% of the studied cohort,20 similar to the data
reported in our 75–79 age stratum population (3.1%).
Our data reinforces the possibility of using new technological
devices to plan large systematic and untargeted screening pro-
grammes. Indeed, the use of a low-cost technological device could
help in the implementation of systematic screening, and measures to
implement stroke prevention in all high risk patients. This would
have an impact of reducing incident stroke due to asymptomatic
AF, which would lead to a significant saving in terms of quality of
life21 and health-related costs.1
Our data strengthen the need for national screening programmes
for AF in European countries, to accomplish identifying AF patients
(often asymptomatic) early, prior to their presentation with compli-
cations such as stroke and heart failure.5 Despite evidence support-
ing their cost effectiveness, nationwide AF screening programmes
have not been uniformly approved, for example, as seen in the
UK (http://legacy.screening.nhs.uk/atrialfibrillation).
Clinical factors significantly associated to the diagnosis of
incident AF were similar to those previously described for AF epi-
demiology,13,14 with the strongest associations seen for older
age and previous stroke. Based on this study, there could be a
role of ECG handheld machines in screening both the general
population and selected cohorts, in relation to concomitant AF
risk factors.
Our data again emphasize how in the general population, the
proportion of AF subjects correctly treated with OAC accord-
ingly to current guidelines seems suboptimal.5 Moreover, we
clearly show the large proportion of newly diagnosed AF patients
at high thrombo-embolic risk where OAC therapy would have
been recommended.5 The issue of the OAC under-treatment
has always been an important problem in the management of
AF patients, as evident by several studies.22,23 However, recent
data from the EORP-AF General Pilot Registry documented a
high proportion (80%) of cardiologist-managed AF patients ad-
hering to international guidelines for stroke prevention.17 The
low number of subjects treated with OAC in our study seems
to underline the gap between highly controlled and selected po-
pulations from randomized controlled trials or those managed by
highly specialized cardiology-based centres, to community-based
observational cohort studies and the ‘real-life’ clinical application
of guidelines.
Moreover, other possible explanations could be related to physi-
cians’ practice. On one side could be the physician’s unawareness
about the most updated international guidelines on the other there
is the possible concern about bleeding risk when using OAC treat-
ment. Indeed, also data coming from the EORP-AF population
showed that a large part of patients, more than 17%, were under-
treated according to their thrombo-embolic risk.24 Indeed, some
evidence seem to suggest that among physicians major bleeding
concern seems to overcome that of a thrombo-embolic event, being
the most feared consequence when treating AF patients.25,26 Fur-
thermore, at the moment no Belgian national guidelines about AF
treatment have been produced, so some physicians, in particular
general practitioners, are unaware about the need of a proper
OAC therapy in some of their patients.
Moving from our study results, it appears clear that a massive
national campaign would be designed to better inform all the phy-
sicians, both specialists and general practitioners, about the most
updated guidelines in evaluating and treating AF patients. In par-
ticular, all of the physicians should be aware about the most reli-
able tools in evaluating patients thrombo-embolic and bleeding
risk (CHA2DS2-VASc and HAS-BLED scores), in order to correct-
ly identify those patients that needed both OAC therapy and spe-
cific interventions to reduce the bleeding risk (i.e. better control
of blood pressure, control of alcohol use, and inadequate use of
antiplatelet and anti-inflammatory drugs),11 especially given the
recent evidence that both patients under- and over-treated with
OAC have a higher risk of major thrombo-embolic events.24 Simi-
larly, all the physicians should be aware about the need of identi-
fying those patients that were more likely to have a better
anticoagulation control and those that were not (using the
SAMe-TT2R2 score) to take the most valuable decision if to pre-
scribe a vitamin K antagonist or a non-vitamin K antagonist oral an-
ticoagulants.11,27 In this sense, the drafting of National Guidelines
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about AF diagnosis, clinical evaluation, and treatment could be a
valuable option.
Limitations
One of the major limitations of our study is the voluntarily nature of
the screening programme. This could have led to an underestima-
tion of both overall and incident AF prevalence. Secondly, the study
questionnaire was designed only to identify the major thrombo-
embolic risk factors (currently used to calculate the CHA2DS2-
VASc score) and did not record any other clinical factors that could
influence AF incidence. Moreover, having the subjects filling the
questionnaire independently may have led to some clinical ques-
tions being misunderstood. Indeed, the self-reported previous AF
diagnosis data could have been affected by reporting bias that could
not be addressed by medical monitoring. Furthermore, when the
use of APT and/or OACwas reported, this was not uniquely related
to the presence of AF, even in those subjects that reported a
previous AF diagnosis.
Conclusions
In a national population screening programme, the prevalence of AF
was 1.4% in the Belgium population. The use of an ECG handheld
machine is feasible to identify a significant number of new AF cases,
most with a high risk of stroke and thrombo-embolism. Given the
low use of OAC among recorded AF patients, greater efforts in
AF detection and treatment are urgently needed to reduce the
burden of stroke associated with this common arrhythmia.
Supplementary material
Supplementary material is available at Europace online.
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Missing ventricular paced events at hourly plus 30-s intervals
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Permanent pacemakers are often implanted after
surgical aortic valve replacement. The proper
pacemaker function is usually confirmed by elec-
trocardiographic monitoring before discharge
of the patient from the hospital. A 31-year-old
Caucasian man who underwent a Bentall proced-
ure received an Advisaw dual-chamber pace-
maker (Medtronic Inc., Minneapolis, MN, USA)
programmed in DDD mode for complete atrio-
ventricular block.
Analysis of the telemetry recordings revealed
the absence of single ventricular paced events
at 60 min plus 30 s intervals (Figure). Upon inter-
rogation, the pacemaker was in DDD pacing
mode, with atrial sensed–ventricular paced
(AS–VP) events, and no abnormal event stored
in memory.
The missing V-Pace is caused by residual elec-
trical disturbance on the ventricular sense while
referencing electrogram. Following an AS, there
was no ventricular blanking, a false ventricular
sense occurred with no VP.
This phenomenon, which has been observed
with various Medtronic dual-chamber pace-
makers (the Advisaw model in particular), might
be manageable by decreasing the ventricular
sensitivity. This phenomenon, limited to dual-chamber pacemakers, seems to be rare and should not prompt an explant of the device.
The full-length version of this report can be viewed at: http://www.escardio.org/Guidelines-&-Education/E-learning/Clinical-cases/
Electrophysiology/EP-Case-Reports.
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